ridaforolimus Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
immunosuppressants, rapamycin derivatives 4778 572924-54-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • deforolimus
  • ridaforolimus
  • AP23573
  • MK-8669
  • jenzyl
an mTOR inhibitor for the treatment of cancer
  • Molecular weight: 990.22
  • Formula: C53H84NO14P
  • CLOGP: 7.20
  • LIPINSKI: 3
  • HAC: 15
  • HDO: 2
  • TPSA: 201.50
  • ALOGS: -6.09
  • ROTB: 8

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 3.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.10 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 46.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EG03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Mammalian target of rapamycin (mTOR) kinase inhibitors
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:68481 mammalian target of rapamycin inhibitor

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.5 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Serine/threonine-protein kinase mTOR Kinase INHIBITOR IC50 9.70 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
D08900 KEGG_DRUG
C1873068 UMLSCUI
CHEBI:82677 CHEBI
CHEMBL2103839 ChEMBL_ID
DB06233 DRUGBANK_ID
11520894 PUBCHEM_CID
7884 IUPHAR_LIGAND_ID
C515074 MESH_SUPPLEMENTAL_RECORD_UI
8822 INN_ID
48Z35KB15K UNII

Pharmaceutical products:

None